2986-LB: Role of BMI in Diabetic Complications and Glycemic Control in the LANDMARC Study: A Subgroup Analysis

Introduction and Objective: BMI significantly influences type 2 diabetes (T2D) management and treatment outcomes. LANDMARC is a 3-year study on people with T2D (PWT2D) in India. This sub-group analysis evaluated BMI-specific glycemic control and outcome. Methods: Evaluable participants were stratified into four BMI categories: underweight, normal, overweight, and obese. Data on macrovascular and microvascular complications, cardiovascular (CV) risk factors, insulin dosing, and glycemic assessments were collected and analyzed across 7 visits (V) over 36 months. Results: Out of 6234 eligible participants, 6203 were evaluable. BMI groups showed slight variations in macrovascular complications with no specific trends in new complications. Microvascular complications were lowest in underweight group and showed marginal differences among other BMI groups. The obese category had a higher percentage of PWT2D (58.57%) with CV risk factors, including hypertension, and dyslipidemia. Insulin dosing varied by BMI; overweight and obese PWT2D required higher basal and prandial insulin doses. Mean HbA1c was >8% at baseline across BMI groups and reduced to <7.5% by V7. Initial higher FPG and PPG levels decreased to near normal by V7 across all BMI groups. Glycemic control improved in all BMI groups at each V (Table). Conclusion: BMI impacts T2D complications and glycemic control, emphasizing the need for BMI-tailored management. Disclosure S. Joshi: None. H. Thacker: Speaker's Bureau; Current; Sanofi. Speaker's Bureau; Ended; Bayer India, GlaxoSmithKline India, Novo Nordisk, Sun Pharmaceutical Industries Ltd. A. Das: Speaker's Bureau; Current; Sanofi. Speaker's Bureau; Ended; Novo Nordisk. N. Rais: Speaker's Bureau; Current; Sanofi. Funding Sanofi (DIREGL08112)